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ABSTRACT
Introduction: Cough is a key symptom of tuberculosis
(TB) as well as the main cause of transmission.
However, a recent literature review found that cough
frequency (number of coughs per hour) in patients
with TB has only been studied once, in 1969. The
main aim of this study is to describe cough frequency
patterns before and after the start of TB treatment and
to determine baseline factors that affect cough
frequency in these patients. Secondarily, we will
evaluate the correlation between cough frequency and
TB microbiological resolution.
Methods: This study will select participants with
culture confirmed TB from 2 tertiary hospitals in Lima,
Peru. We estimated that a sample size of 107 patients
was sufficient to detect clinically significant changes in
cough frequency. Participants will initially be evaluated
through questionnaires, radiology, microscopic
observation drug susceptibility broth TB-culture,
auramine smear microscopy and cough recordings.
This cohort will be followed for the initial 60 days of
anti-TB treatment, and throughout the study several
microbiological samples as well as 24 h recordings will
be collected. We will describe the variability of cough
episodes and determine its association with baseline
laboratory parameters of pulmonary TB. In addition, we
will analyse the reduction of cough frequency in
predicting TB cure, adjusted for potential confounders.
Ethics and dissemination: Ethical approval has
been obtained from the ethics committees at each
participating hospital in Lima, Peru, Asociación
Benéfica PRISMA in Lima, Peru, the Universidad
Peruana Cayetano Heredia in Lima, Peru and Johns
Hopkins University in Baltimore, USA. We aim to
publish and disseminate our findings in peer-reviewed
journals. We also expect to create and maintain an
online repository for TB cough sounds as well as the
statistical analysis employed.
INTRODUCTION
Tuberculosis (TB) is an infectious disease,
and was responsible for 9.6 million new cases
and 1.5 million deaths in 2014.1 TB is trans-
mitted in the air2 3 and cough is the most
important cause of transmission.4 Cough in
people with pulmonary TB disease arises as a
result of the inﬂammatory response to myco-
bacterial pulmonary infection. A reduction
in cough is assumed to represent adequate
response to treatment, and to result in
decreased risk of spread of infection. Despite
its crucial role in TB transmission, a recent
literature review5 reported that cough fre-
quency during TB therapy has not been
studied since the work carried out by
Loudon in the 1960s.6 7 Thus, longitudinal
cough frequency studies in TB are needed.
Loudon described cough frequency in 8 h
overnight periods for 9 weeks. All sounds
with amplitude and frequency consistent
with possible cough events were recorded
and then manually reviewed.8 His ﬁndings
show a twofold reduction in the ﬁrst 2 weeks
of treatment, from a mean of 13.6 to 4.75
coughs/h.7 Mycobacterium tuberculosis colony
forming units (CFU) also reduced signiﬁ-
cantly from 106 at baseline to 103 2 weeks
Strengths and limitations of this study
▪ The algorithm employed in this project has been
validated specifically for patients with pulmonary
tuberculosis (TB), which enables us to use this
algorithm in our patients.
▪ A strength of this project is that its results will
reflect actual cough frequency episodes in pul-
monary TB by utilising 24 h recordings in the
patients’ normal-day settings (traffic, dogs
barking, etc). We expect that this will generate a
novel method of evaluating cough in TB that can
be used in real-world scenarios.
▪ Our study has the limitation that recordings have
been processed through a semiautomated algo-
rithm. To decrease time constraints, our long-
time goal is to create a fully automated process-
ing system. We anticipate that experience gained
with semiautomated analysis will aid us in devel-
oping future algorithms.
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later.9 10 This evidence led to the idea that drug-
susceptible patients with TB become sufﬁciently non-
infective by the second week of treatment that they no
longer pose a risk to others. This and other evidence
led to the often-used policy that 2 weeks was the neces-
sary duration of respiratory isolation for newly diagnosed
patients started on appropriate treatment. Current evi-
dence11 and guidelines afﬁrm this position;12–14
however, this 2-week policy has been criticised.15 16 Our
group has shown that drug-susceptible patients with TB
remain sputum culture positive for longer.17 18 Most
importantly, the assumption that patients with TB are no
longer coughing at 2 weeks has never been
corroborated.
The 2015 CHEST guidelines recommend acoustic
parameters to evaluate the frequency of cough.19 In
order to ensure accurate measurement, it is important
to use a standardised method such as automated cough
counting with a validated algorithm. Despite the recently
growing literature on this topic, these methods are prin-
cipally being used in the ﬁeld of non-infectious chronic
disease.20–25 While algorithms for cough counting have
been validated,26–30 our research protocol appears to be
the ﬁrst to do so speciﬁcally in patients with pulmonary
TB.31 32
To address this knowledge gap, we have developed the
Cayetano Cough Monitor (CayeCoM) and here describe
a protocol for it to be used to study cough frequency in
patients with pulmonary TB.
METHODS
Study objectives
The primary objective of this study is to describe cough fre-
quency patterns in adults with pulmonary TB before
and after treatment initiation.
The second objective of this study is to determine baseline
characteristics that correlate with cough frequency, such
as patient demographics, radiological ﬁndings, presence
of multidrug-resistant TB (MDR-TB) and HIV status.
The third objective of this study is to test for an association
between changes in cough frequency and microbio-
logical resolution of TB disease during therapy.
Study design
This prospective cohort study will follow adult patients
with pulmonary TB throughout their treatment period
in Lima, Peru.
Participants with a conﬁrmed or suspected diagnosis
of active pulmonary TB will be referred to our study
team. After obtaining written informed consent, we will
record coughs prior to initiation of TB treatment.
Participants will provide us with early morning sputum
samples that will be tested for active pulmonary TB
disease by testing at least one sputum sample using the
microscopic observation drug susceptibility (MODS)
broth culture assay33–35 and auramine smear microscopy
to assess the bacillary load.
Patients in whom the pulmonary TB diagnosis is con-
ﬁrmed by MODS will receive treatment delivered by the
National TB Programme as per standard practice.36
Figure 1 summarises the data to be collected at baseline
and during the 60 days of follow-up.
Study sites
Peru has one of the highest TB incidence rates in the
Americas.37 More than one-third of the incident TB
cases in the Andean region are from Peru. With respect
to rates of MDR-TB and extensively drug-resistant
(XDR) TB, Peru ranks ﬁrst in all of the Americas.
However, under-reporting in the region may contribute
to Peru’s over-representation, as shown in the latest Pan
American Health Organisation (PAHO) report.37
Within Peru, Lima and its metropolitan area account
for most cases of MDR-TB and XDR-TB.38 Thus, we will
recruit patients from two hospitals: Hospital Nacional
Dos de Mayo (HNDM), located in the historic centre of
Lima; and Hospital Nacional Daniel Alcides Carrión,
located in Callao and which belongs to Lima’s metropol-
itan area.
Our main site, HNDM, is a 650-bed teaching and
public national tertiary referral hospital run by the
Peruvian Ministry of Health (MINSA). It provides ser-
vices to the poor population from the surrounding inner
city area. HNDM is the only hospital in Peru with a nega-
tive pressure ward available for patients with TB. Our sec-
ondary site is another tertiary referral hospital run by
MINSA, Hospital Nacional Daniel Alcides Carrión. This
462-bed teaching health facility lies in the Callao region.
Study population
The infectious disease and pulmonary physicians will
refer participants to the research team. Criteria for
referral are suspicion of active pulmonary TB or a con-
ﬁrmed case of active pulmonary TB which has not yet
started treatment. Active pulmonary TB is deﬁned by a
positive MODS culture result. Participants will be
excluded if they were <18 years of age, pregnant, have
started a new treatment regimen for TB within the past
7 days, or are unable or unwilling to provide informed
consent. If a patient changes the treatment regimen, for
example, due to treatment failure or to an adverse drug
reaction, this would also be considered as a new
regimen. Pregnancy is deﬁned by a positive result on
the serum or urine β-human chorionic gonadotropin
(β-hCG) assay.
Outcomes and case definitions
The primary outcomes for this study are cough fre-
quency and microbiological data from serial sputum
samples. Cough frequency is deﬁned as the number of
cough episodes, or cough epochs, within a time period.
Cough epochs are deﬁned as cough events that are
within a 2 s period frame.32
Regarding microbiological data, participants will be
entered into the study if they have a positive culture
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result. Treatment regimens will be adjusted as needed by
the treating team based on the results of the MODS
drug-susceptibility testing from their sputum. Our study
team will not be involved in the treatment regimen
selection.
Sputum smear conversion is deﬁned as three consecu-
tive smear-negative results, collected at least 8 h apart
after initial smear positivity at diagnosis.12 Culture con-
version is deﬁned as two consecutive negative culture
results, taken at least 30 days apart. This last deﬁnition is
the one used in the MINSA36 and is recommended by
the WHO.39 The date of conversion will be considered
as the date of the ﬁrst negative sputum smear or culture
contributing to conversion.
Secondary outcomes include weight, temperature and
radiological characteristics. When possible, radiological
interpretation data from chest ﬁlms and thoracic CT
scans will be obtained. Chest X-ray ﬁlms (CXR) provide
a high negative predictive value for the presence of
active TB,40 but CXR might be normal when in fact
there is parenchymal disease.41 More speciﬁcally, CT
scans correctly determine pulmonary TB cases in 91%
of cases and CXR in only 49% of cases.41–44 In addition,
CT scans provide higher sensitivity for the detection of
lymphadenopathy, early bronchogenic spread and to
evaluate cavitation and disease activity.44
Sample size
In a pilot study, we estimated that the frequency of
cough in patients with TB before receiving treatment is
approximately 327 coughs during a 24 h period with an
SD of approximately 50. A sample size of 97 patients
would enable us to detect a conservative decrease in the
mean number of coughs in the 24 h period of at least 45
coughs after 2 weeks of treatment, with a 5% type I
error probability and 80% power.
Under the hypothesis that patients with TB before
treatment experience a high cough frequency, we
hypothesise that after 2 weeks of anti-TB treatment,
there will be a clinical response accompanied by a sig-
niﬁcant reduction in cough frequency. Response is
deﬁned as at least a twofold reduction in cough fre-
quency, which was previously shown to occur within the
ﬁrst 2 weeks of treatment.7 For power calculations, it is
assumed that all participants will eventually respond to
treatment, according to our deﬁnition of response, and
that once cough frequency has reduced in an individual
it will not rise again. We assume that after the 2 weeks of
Figure 1 Flow diagram for CayeCoM study. CayeCoM, Cayetano Cough Monitor; MODS, microscopic observation drug
susceptibility; TB, tuberculosis.
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treatment approximately 10% of patients would main-
tain a high frequency of cough. Thus, a sample size of
97 patients will allow us to detect an OR of at least 3.2
for the risk of patients not responding to TB treatment
in 2 weeks of therapy, under a 95% signiﬁcance and
80% power. An additional 10% of patients will be
recruited to correct for patients who do not complete all
of the study procedures. Thus, we will aim to recruit a
total of 107 patients.
Study organisation
The Asociación Benéﬁca (A.B.) PRISMA and
Universidad Peruana Cayetano Heredia in Lima, Peru
will provide local administrative oversight. Overseas,
oversight will be conducted by Johns Hopkins University
in Baltimore, Maryland, USA.
In Lima, the Pampas ofﬁce of A.B. PRISMA will
provide operations and logistic support for ﬁeldwork.
An additional collaborating signal processing team will
be based locally in the Universidad Nacional de
Ingeniería, Lima, Peru, as well as at Tufts University,
Massachusetts, USA.
Our collaborating biostatisticians are based at Tufts
University, Tulane University and Universidad Peruana
Cayetano Heredia, Lima, Peru. All investigators are
involved in protocol design and technical support and
will remain involved in the ongoing analyses.
Personnel, training and logistics
Nurses have been trained by study staff to obtain sputum
samples in a best-practice fashion based on previous
work,45 46 and to operate and troubleshoot all recorder
devices, memory cards and battery packs. We will adhere
to recommended infection prevention and control prac-
tices for TB to reduce biorisk in healthcare professionals
and patients.47 Written informed consent is required
prior to research participation. At the time of enrol-
ment, participants will follow the procedures outlined in
ﬁgure 1.
Participants with active pulmonary TB will be followed
throughout their TB treatment. After the identiﬁcation
of active pulmonary TB and on the basis of convenience,
participants who consent will undergo CXR and a non-
contrast thoracic CT scan.
The ﬁrst day of a new TB treatment regimen is
deﬁned as ‘day 0’. An initial questionnaire will be com-
pleted on that day (see online supplementary ﬁle 1).
It should be mentioned that we used a 5-level ordinal
scale instead of 10 to make it simpler for our intervie-
wees. We have found it easier in this setting for research
participants to interpret 5-levels each with deﬁning
words (never, little, much, almost always and always)
rather than 10. This questionnaire is similar to the one
that was employed in a previous study.48 Baseline cough
frequency will be obtained by performing an audio
recording of the patients before they obtain their micro-
biological results, which is usually a few days prior to
treatment initiation. Hence, participants will be
recorded from at least one day prior to treatment and
throughout their ﬁrst two weeks of treatment. They will
subsequently be recorded for 24 h on or around days 21,
30 and 60 of treatment, although up to two days’
date deviation for Sundays and public holidays will be
allowed.
Recordings will start at 09:00 and will be as continuous
as possible. Occasionally, incomplete recordings could
be obtained due to malfunction of equipment or patient
non-compliance. On the recording days, clinical data
will be gathered, including: weight, temperature and
sputum samples for smear and MODS results. The
number of days to culture positivity in the MODS liquid
culture assay will be recorded in order to assess the
microbiological burden in the patients’ samples, based
on prior work done with a similar technique.49
Audio recording
Design of the audio recording equipment, the CayeCoM
device, builds on previous chronic cough ambulatory
audio recordings.27 50 51 The CayeCoM device is a
Marantz PMD 620 professional handheld recorder, using
an Audio-Technica AT899 sub-mini microphone with an
AT8537 microphone power module. The microphone
will be attached at the patient’s lapel as shown in
ﬁgure 2. The recorder is adapted to work with an exter-
nal lithium battery supply (Enix Energies 800040) to
enable continuous 24 h recordings. The audio is
recorded onto a SanDisk SDHC 8 GB card, at a sample
rate of 48 kHz, encoding 64 kbps in mono in MP3
format. The audio equipment is kept inside a basic pack
connected to a lapel microphone. Batteries and SD
cards will be exchanged daily by the study nurses. In
pilot research, participants tolerated the audio equip-
ment well, wearing them 24 h a day and taking them off
only to bathe.
Processing of audio recordings
The recorded signals will be analysed after all patient
recordings are completed. For cough analysis, software
developed by our group and previously described in
detail will be used.31 32 Thus, we provide only a brief
review here and refer interested readers to our previous
publications.
Brieﬂy, cough recordings will be analysed using a
two-step algorithm: ﬁrst, event detection, followed by
event classiﬁcation into cough versus non-cough.
Detection of acoustic events will be based on the signal
energy proportional to the square of the voltage of the
signal. An acoustic event will detect if the signal energy
exhibited a rapid increase above a time-varying baseline
estimate of ambient noise. The next stage of processing
seeks to classify detected events. Here, the spectral fea-
tures of each time frame in the acoustic event are char-
acterised using Mel-frequency cepstral coefﬁcients and
their derivatives. As described in detail elsewhere,32 a
training data set will be used to develop a classiﬁer
based on the sequential minimal optimisation (SMO)
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algorithm. On the basis of classiﬁer outputs, each acous-
tic event will be marked as ‘cough’ or ‘not-cough’.
Isolated cough events will be automatically combined
into cough epochs, or bursts of closely spaced individual
coughs, following previous research.52 We will employ a
deﬁnition of cough epochs, as deﬁned in the ‘Outcomes
and case deﬁnitions’ section above. Note that within the
cough literature, a variety of metrics are available for
describing a cough, and there is no clear evidence as to
which of them are most clinically meaningful. We have
previously published a review and discussion of these
various metrics (number of individual coughs, number
of cough bouts or epochs, number of 1 s periods con-
taining cough, etc).32
We will employ a semiautomated approach in which
cough epochs that are automatically detected will then
be manually reviewed to eliminate false positives. This is
necessary as our recordings will be made in very noisy
environments (outside clinical settings) and false
detection rates for a fully automated system remain high.
For this study, a simple graphical user interface will be
constructed to allow nurses to review automatically
detected epochs, enabling them to listen to each as
often as needed, and then to either accept or reject
the detected cough. Thus, the review of automatically
detected coughs acts to eliminate algorithmic false-
positive coughs.
Validation: The approach described in the above para-
graphs was previously validated using as the gold stand-
ard a fully manual review of 60 ﬁles (15 participants, 4
randomly selected time periods per participant) in
which two nurses listened to all ﬁles in their
entirety.32 Since nurses only manually marked the start
of each cough, validation was compared on the basis of
the epoch deﬁnition described above. The semiauto-
mated approach described above gave 75.5% sensitivity
in detecting coughs (a true-positive rate of 6.8/h) with
an average false-positive rate of 0.5/h.32 While the semi-
automated approach does require time for human
review, the initial automated step will remove the large
majority of possible events. Thus, on average, review
time is reduced by nearly two orders of magnitude com-
pared with a fully manual review in which the entire
recording is reviewed. We will also maintain the privacy
of participants, as non-cough events, such as conversa-
tion, will never be reviewed by the human ear.
Microbiology
The microbiological tests will be carried out in a
Biosafety Containment Level 3 research laboratory situ-
ated within Universidad Peruana Cayetano Heredia in
Lima, Peru. The sputum samples will be digested and
decontaminated by the standard NaOH-n-acetyl cysteine
method.53 For smear microscopy, an aliquot of 100 µL is
stained with Auramine O and examined with ×400 mag-
niﬁcation. Results are determined as negative, pauciba-
cillary (1–19 acid-fast bacilli (AFB) visualised in 40
ﬁelds), 1+ (20–199 AFB visualised in 40 ﬁelds), 2+ (5–50
AFB per ﬁeld) and 3+ (>50 AFB per ﬁeld). Culture and
MODS susceptibility testing will be performed with the
remaining samples, according to standard protocols.33–35
Radiology
Radiological information will be gathered when possible
on a convenience basis. Priority will be given to CT
scans, since they have been shown to be more sensitive
in general.44 A previous study determined that the sensi-
tivity for the prediction of active TB through CT scans
was 96%, whereas for CXR it was merely 48%.54 Films
will be read by a local radiologist and a US board-
certiﬁed radiologist blinded to the patient’s demograph-
ics and outcomes. They will provide an interpretation
that is standardised as per our study protocol to describe
radiological ﬁndings including cavitation, consolidation,
lymphadenopathy and effusions (see online supplemen-
tary ﬁle 2). We will explore whether these radiological
ﬁndings are predictive of microbiological burden and
cough frequency.
Figure 2 Picture of the Cayetano Cough Monitor (CayeCoM).
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Cavitations will be further described by the size, loca-
tion, presence or absence of an air–ﬂuid level, and
cavity wall thickness based on prior work that shows the
relevance of these ﬁndings to pulmonary TB and, most
importantly, to infectivity.7 55–58 It is therefore important
to determine cavitations, and as Im et al55 have shown,
CT correctly identiﬁes cavitations in 58% of cases,
whereas CXR only identiﬁes 22%.
Statistical methodology and analysis
All questionnaire data will be double digitised from
paper forms using Visual FoxPro 9 Service Pack 2
(Microsoft Corp. Redmond, Washington, USA) and
microbiological data will be double entered using
Microsoft Access 2010 (Microsoft Corp. Redmond,
Washington, USA). These two data sets will be cross-
compared for validity and errors. From these data,
descriptive statistics will be tabulated and graphed.
Cough analysis processing results will be stored as
Matlab (Mathworks, Inc, Natick, Massachusetts, USA)
ﬁles containing information regarding each event and
its timestamp. Algorithmically detected coughs will be
annotated in the ﬁles. After manual review, isolated
cough events will be grouped into cough epochs, or
bursts of closely spaced individual coughs within 2 s, fol-
lowing published work on cough evaluation.52
For the ﬁrst study objective of describing cough frequency,
cough epochs will be plotted throughout the day, and
cough frequency will be summarised as the frequency of
cough epochs per hour. Positively skewed cough data
may be log-transformed to facilitate data visualisation
and analysis. To address the second study objective, correl-
ation of characteristics with cough frequency, we will use
generalised estimating equations (GEE) based Poisson
or negative binomial regression with baseline microbio-
logical status, and trigonometric (sine/cosine) terms to
model circadian periodicity, as the independent vari-
ables. In addition, a multiple logistic regression in a lon-
gitudinal generalised linear model (GLM) framework
analysis will evaluate a function of sputum bacillary load
and with cough frequency that we propose as a potential
predictor of TB transmissibility. In all cases, we will
correct for outliers, and nested models will be compared
using the likelihood ratio test. We will also consider vari-
ables such as gender, HIV status, drug resistance and
history of TB in our analysis, either by stratifying or by
adjusting for these variables in our models.
To test the association between cough frequency and
microbiological resolution of TB disease associated with
the third aim of this study, time-to-event survival analyses
where the outcomes of interest are sputum smear con-
version, and culture conversion, as deﬁned above, and
the primary predictors of interest are cough frequency
at baseline, during treatment, and time to twofold reduc-
tion in cough frequency. In addition, secondary analyses
of weight, temperature and radiological characteristics
will be conducted using GLMs and GEE logistic regres-
sion as appropriate.
Dissemination
Written informed consent will be obtained from all par-
ticipants. Test results will be delivered by telephone or at
subsequent visits at which time a team physician or
nurse will be able to explain the results to the study par-
ticipants. TB treatment remains the responsibility of the
medical staff in charge and the National TB
Programme. We aim to publish and disseminate our
results once the project is complete. We also expect to
create and maintain an online repository for TB cough
sounds as well as the statistical analysis employed.
DISCUSSION
We will determine cough frequency before and during
anti-TB treatment using the CayeCoM device. We will
identify baseline predictors of cough frequency during
TB treatment and evaluate the correlation between
change in cough frequency and microbiological
resolution.
The medical literature currently lacks information
about cough frequency in TB. As recently noted by
Turner and Bothamley,5 cough frequency in patients
undergoing TB treatment has only been studied once,
almost half a century ago.6 7 This previous study has the
limitation of only being conducted within an 8 h period,
overnight, and thus there is no information on daytime
coughing or the effect of the diurnal rhythm on cough.
A similar study58 demonstrated that the severity of cough
and pathological chest X-ray ﬁndings were associated
with higher levels of TB transmission. However, their
study did not measure cough frequency but instead
focused on a participantive characteristic: cough severity.
It should be noted that to assess cough frequency, one
must utilise objective acoustic parameters, since self-
reported cough is unreliable.19 As reported in abstract
form, the objective acoustic Leicester Cough Monitor
(LCM) has been used to evaluate 24 h cough recordings
in patients with pulmonary TB before starting treatment,
showing that cough frequency is reduced at night.59
This further justiﬁes re-evaluation of Loudon’s overnight
study.
Our project has several strengths and limitations. An
important strength is the generation of 24 h cough
recordings, which will provide lengthy recordings, will
enable evaluation of cough patterns at different times of
day, and also have the beneﬁt of being recorded during
a normal day in real-world settings where we expect our
device to be used in the future. Normal day recordings
are confounded by background noise, which is a chal-
lenge for analysis of cough recordings, considering that
trafﬁc and environmental noise (such as dogs barking,
music and television) may generate noises similar to
cough. To diminish this effect, we have incorporated a
time-varying estimate of the noise background as well as
a data quality control. Having a semiautomated algo-
rithm is a limitation, since it requires time and human
input, as well as a strength since the human ear is the
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gold standard for determining the characteristic sound
of cough. Similar to Loudon and Romans’8 proposal,
our algorithm will help to screen and reduce the length
of the recordings to ∼5% of their original length,
without affecting sensitivity and improving speciﬁcity.32
In the long term, we aim to improve our algorithm (ie,
fully automated processing), and we anticipate that
experience gained with semiautomated analysis will aid
us in this process. In addition, we are now developing
second-generation devices where the validity is improved
by employing accelerometers. This study is limited by
restriction to only non-pregnant adults because this is
the population for which the algorithm has been vali-
dated. However, future research is planned to include
these important vulnerable populations.
CayeCoM has been validated for 24 h recordings,32
whereas PulmoTrack (PulmoTrack-CC, KarmelSonix,
Haifa, Israel) was validated for 25 min29 and the Hull
Automatic Cough Counter for 1 h recordings.27 Other
systems have also validated their algorithms for 24 h
recordings, such as the LCM,28 60 VitaloJAK30 and the
LifeShirt System.26 However, in contrast to our study,
none of these algorithms have been validated either for
pulmonary TB or within real-life settings (eg, trafﬁc).
We expect that this project will generate a novel method
to evaluate treatment response. In future studies, we
intend to better assess infectiousness by additionally
quantifying TB in cough-generated aerosols.
Cough frequency should provide additional informa-
tion regarding the evolution of the patients’ medical
condition. If a correlation with bacteriological treatment
response is demonstrated, then this would have the
potential to contribute to patient management without
relying on a laboratory in adult patients with pulmonary
TB. However, we should be careful when monitoring
patients with TB since some may worsen after an initial
positive response to therapy. It could assist with deci-
sions regarding the need for the ongoing respiratory
isolation of patients, treatment duration and identiﬁca-
tion of patients with treatment failure who may need
modiﬁcation of their treatment regimens. The device
also has the potential to be used remotely, as in tele-
medicine. This is potentially important in a country
such as Peru, where the majority of doctors live in the
capital, leaving most of the country without a physician
in their region. Cough monitoring devices seem challen-
ging; however, we believe that this is the ﬁrst step
towards telemedicine in cough-TB. In Peru, many rural
areas do not have facilities for laboratory diagnosis, but
have at least one physician or healthcare professional.
They may be trained in placing these devices. We are
also working on making devices smaller, cheaper and
easier to use.
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